Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Structure Therapeutics Inc GPCR

Healthcare
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GPCR)

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

GlobeNewswire March 8, 2024

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire March 8, 2024

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GlobeNewswire December 18, 2023

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire November 14, 2023

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

GlobeNewswire September 29, 2023

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

GlobeNewswire September 29, 2023

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire August 10, 2023

Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors

GlobeNewswire August 3, 2023

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

GlobeNewswire June 7, 2023
View More News ››

Opinion & Analysis (NDAQ:GPCR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GPCR)

Be the first to post on this bullboard.

Liberty Defense Holdings Ltd.

Liberty Defense Holdings Ltd.

Liberty Defense provides multi-technology security solutions for concealed weapons detection in high volume foot traffic ...
View More »